Status:
RECRUITING
Intraoral Hypothermia Device for Preserving Taste During Radiation
Lead Sponsor:
Henry Ford Health System
Conditions:
Head and Neck Cancer
Taste Dysfunction
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this r...
Eligibility Criteria
Inclusion
- Patients being treated with combination radiation therapy and chemotherapy (definitive) for locally advanced (AJCC 8th cT3-4 or cN+) squamous cell carcinoma of the larynx.
- Age ≥ 18.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Patients will engage in the informed consent process and provide study-specific informed consent prior to study entry and must be able to fill out toxicity and quality of life related questionnaires.
- Patients should be concurrently treated with any of the following chemotherapy drugs: cisplatin, carboplatin, and cetuximab.
Exclusion
- Patients receiving other forms of therapy intended to reduce taste dysfunction.
- Patients with metastatic disease.
- Patient with allergies or hypersensitivity to materials in the intraoral bolus.
- Patients who have received prior chemotherapy or radiation therapy for head and neck cancer.
- Patients who decline to use or cannot tolerate the intraoral device.
- Patients who are current or recent (within 3 months of treatment initiation) cigarette smokers.
- Patients who are unable to complete the required forms; however, verbal completion is adequate if recorded on the form daily.
- Patients with uncontrolled serious illness including, but not limited to, ongoing or serious active infection requiring IV antibiotics for over 30 days, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, immunocompromised state, significant hepatic insufficiency, significant hematological disease, and any serious or unstable psychological condition.
- Patients who are on any of the following medication that cannot find a suitable substitute during the study period: acetazolamide, maribavir (TAK-620, Phase 3 trial drug), eszopiclone, topiramate, captopril, lithium, procainamide, terbinafine, and amiodarone.
- Patients who have taste loss at baseline, assessed subjectively and objectively at the first encounter, will be excluded from the study and all analysis. They will be replaced with a new patient.
- Patients who have tested positive for COVID-19 during the study period.
Key Trial Info
Start Date :
November 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06579248
Start Date
November 12 2024
End Date
August 30 2025
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Health System
Detroit, Michigan, United States, 48202-2689